Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 21 of 21 publications.

Davenport E, Zhou X, Wang J, Nunna S, Oberdhan D, Fernandes A, Mekahli D. Disease burden and disease progression of young adult patients with autosomal dominant polycystic kidney disease. Poster presented at the National Kidney Foundation 2023 Spring Clinical Meeting; April 11, 2023. Austin, TX. [abstract] Am J Kidney Dis. 2023 Apr 1; 81(4, Supple 1):S102. doi: 10.1053/j.ajkd.2023.01.349

McLauchlan L, Lancaster K, Kearnes M, Mellor R, Ritter A. "It's professional but it's personal": participation, personal connection, and sustained disagreement in drug policy reform. Int J Drug Policy. 2022 Dec;110:103903. doi: 10.1016/j.drugpo.2022.103903

Lennon RP, Demetriou TJ, Khalid MF, Van Scoy LJ, Miller EL, Dong H, Zgierska AE. Characteristics and outcomes among hospitalized COVID-19-positive patients in a nonurban environment. Mil Med. 2021 Nov 2;186(11-12):1088-92. doi: 10.1093/milmed/usab044

Zhou X, Davenport EK, Ouyang J, Krasa H, Garbinsky D, Agarwal I, Oberdhan D. Population characteristics across a pooled database of multiple Autosomal Dominant Polycystic Kidney Disease (ADPKD) clinical studies. Poster presented at the 2020 National Kidney Foundation Spring Clinical Meeting; March 2020. New Orleans, LA. [abstract] Am J Kidney Dis. 2020 Apr; 75(4):663.

Mader G, Purser M, Mladsi D, Sanon M, Oberdhan D, Watnick T, Seliger S. Benefit of tolvaptan on time to End-stage Renal Disease (ESRD) for patients with rapidly progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD): a disease progression model. Poster presented at the 2020 National Kidney Foundation Spring Clinical Meeting; March 2020. New Orleans, LA. [abstract] Am J Kidney Dis. 2020 Apr; 75(4):603.

Butler AM, Layton JB, Dharnidharka VR, McGrath LJ. Correspondence: In reply to 'High-dose versus standard-dose influenza vaccine in hemodialysis patients'. Am J Kidney Dis. 2020 Mar;75(3):456-7. doi: 10.1053/j.ajkd.2019.11.002

Butler AM, Layton JB, Dharnidharka VR, Sahrmann J, Seamans MJ, Weber DJ, McGrath L. Comparative effectiveness of high-dose versus standard-dose influenza vaccine among patients receiving maintenance hemodialysis. Am J Kidney Dis. 2020 Jan;75(1):72-83. doi: 10.1053/j.ajkd.2019.05.018.

Assimon MM, Brookhart MA, Fine JP, Heiss G, Layton JB, Flythe JE. A comparative study of carvedilol versus metoprolol initiation and 1-year mortality among individuals receiving maintenance hemodialysis. Am J Kidney Dis. 2018 Sep;72(3):337-48. doi: 10.1053/j.ajkd.2018.02.350.

Gourdet C, Giombi KC, Kosa K, Wiley J, Cates S. How four U.S. states are regulating recreational marijuana edibles. Int J Drug Policy. 2017 May;43:83-90. doi: 10.1016/j.drugpo.2017.01.018.

Kosa KM, Giombi KC, Rains CB, Cates SC. Consumer use and understanding of labelling information on edible marijuana products sold for recreational use in the states of Colorado and Washington. Int J Drug Policy. 2017 May;43:57-66. doi: 10.1016/j.drugpo.2017.01.006

Price KJ, Knowles JA, Fox M, Wales JK, Heller S, Eiser C, Freeman JV, Brennan A, Basarir H, Stevens K, McPherson A. Effectiveness of the Kids in Control of Food (KICk–OFF) structured education course for 11–16 year olds with type 1 diabetes. Diabet Med. 2016 Feb;33(2):192-203. doi: 10.1111/dme.12881

Wolowacz S, Pearson I, Shannon P, Chubb B, Gundgaard J, Davies M, Briggs A. Development and validation of a cost-utility model for Type 1 diabetes mellitus. Diabet Med. 2015 Aug;32(8):1023-35. doi: 10.1111/dme.12663

Thokala P, Kruger J, Brennan A, Basarir H, Duenas A, Pandor A, Gillett M, Elliott J, Heller S. Assessing the cost‐effectiveness of type 1 diabetes interventions: the Sheffield type 1 diabetes policy model. Diabet Med. 2014 Apr;31(4):477-86. doi: 10.1111/dme.12371

Fleming A, Philip S, Prescott G, Olson J, Sharp P. Presence of retinopathy and a high microaneurysm count increase the risk of subsequent cardiovascular disease. Poster presented at the Diabetes UK professional conference 2014; March 5, 2014. Liverpool, UK. [abstract] Diabet Med. 2014 Mar 1; 31(S1):86-7. doi: 10.1111/dme.12378_2

Kruger J, Brennan A, Thokala P, Basarir H, Jacques R, Elliott J, Heller S, Speight J. The cost-effectiveness of 5-week versus 1-week DAFNE structured education in type 1 diabetes: a preliminary evaluation using the Sheffield type 1 diabetes policy model. Diabet Med. 2013 Oct;30(10):1236-44. doi: 10.1111/dme.1227

Goatman KA, Philip S, Fleming AD, Harvey RD, Swa KK, Styles C, Black M, Sell G, Lee N, Sharp PF, Olson JA. External quality assurance for image grading in the Scottish diabetic retinopathy screening programme. Diabet Med. 2012 Jun 1;29(6):776-83. doi: 10.1111/j.1464-5491.2011.03504.x

Bradbury BD, Brookhart MA, Winkelmayer WC, Critchlow CW, Kilpatrick RD, Joffe MM, Feldman HI, Acquavella JF, Wang OH, Rothman KJ. Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in non-experimental research: strengths and limitations. Am J Kidney Dis. 2009 Sep 1;54(3):554-60.

Bradbury BD, Wang O, Critchlow CW, Rothman KJ, Heagerty P, Keen M, Acquavella JF. Relative mortality and epoetin alfa dose in hemodialysis patients - Reply. Am J Kidney Dis. 2008 May 1;51(5):865-6.

Bradbury BD, Wang O, Critchlow CW, Rothman KJ, Heagerty P, Keen M, Acquavella JF. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis. 2008 Jan 1;51(1):62-70.

Nielsen GL, Norgard B, Puho E, Rothman KJ, Sorensen HT, Czeizel AE. Risk of specific congenital abnormalities in offspring of women with diabetes. Diabet Med. 2005 Jan 1;22(6):693-6.

Estrada CA, Unterborn JN, Price J, Thompson D, Gibson L. Judging the effectiveness of clinical pathways for pneumonia: the role of risk adjustment. Eff Clin Pract. 2000 Sep 1;3(5):221-8.